Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 9/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | PDE6D | O43924 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938873 | 1.00 | DDB1 (0.38) | DDB1CRBNCHRM3MAP1LC3BSTAT3 | |
| SCHEMBL19889406 | 0.90 | DDB1 (0.42) | DDB1CRBNMAP1LC3B | |
| SCHEMBL4938307 | 0.90 | TMEM97 (0.41) | DDB1CRBNMAP1LC3B | |
| SCHEMBL4938313 | 0.90 | TMEM97 (0.41) | DDB1CRBNMAP1LC3B | |
| SCHEMBL4939014 | 0.89 | DDB1 (0.41) | DDB1CRBNCHRM3MAP1LC3B | |
| SCHEMBL4939022 | 0.89 | DDB1 (0.41) | DDB1CRBNCHRM3MAP1LC3B | |
| SCHEMBL4937229 | 0.89 | MAP1LC3B (0.40) | CHRM3MAP1LC3BLTA4H | |
| SCHEMBL4937222 | 0.89 | MAP1LC3B (0.40) | CHRM3MAP1LC3BLTA4H | |
| SCHEMBL4938877 | 0.87 | DDB1 (0.39) | DDB1CRBNCHRM3STAT3PDE6D | |
| SCHEMBL4939806 | 0.84 | CRBN (0.46) | DDB1CRBNMAP1LC3BSTAT3PDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10406147-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2019-09-10 | — | — | US | disclosed |
| US-20190247383-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| US-10166222-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20180050025-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2018-02-22 | — | — | US | disclosed |
| US-9669015-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2017-06-06 | — | — | US | disclosed |
| US-20150272940-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-9085563-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-07-21 | — | — | US | disclosed |
| US-20140179737-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-8637545-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2014-01-28 | — | — | US | disclosed |
| EP-1867649-B1 | PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2012-12-12 | — | — | EP | disclosed |
| US-20080051432-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2008-02-28 | — | — | US | disclosed |
| EP-1867649-A1 | PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050025-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF9, TNFRSF1A, NGFR | DDB1 2855/4885CRBN 949/4885CHRM3 111/4885 |
| US-10406147-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TNF, TNFRSF1A, TNFRSF9 | DDB1 2336/4885CRBN 896/4885CHRM3 137/4885 |
| US-10166222-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TNFRSF1A, TNFRSF9, NGFR | DDB1 2770/4885CRBN 1007/4885CHRM3 109/4885 |
| US-20150272940-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, TNFRSF9 | DDB1 2336/4885CRBN 896/4885CHRM3 137/4885 |
| US-20190247383-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, TNFRSF9 | DDB1 2373/4885CRBN 862/4885CHRM3 164/4885 |
| US-20080051432-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, TNFRSF9 | DDB1 2336/4885CRBN 896/4885CHRM3 137/4885 |
| US-20140179737-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, TNFRSF9 | DDB1 2336/4885CRBN 896/4885CHRM3 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.